Osiris Therapeutics (OSIR) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Osiris Therapeutics (OSIR) PT Raised to $25 at Brean Capital; Grafix Positioned Well for Accelerated Growth
August 6, 2015 8:26 AM EDTBrean Capital analyst Difei Yang reiterated a Buy rating and raised the price target on Osiris Therapeutics (NASDAQ: OSIR) to $25.00 (from $19.00), saying Grafix is positioned well for accelerated growth.
Yang commented, "Q2 met expectations on revenue but missed on... More
